Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Your healthcare provider can design a personalized tapering schedule based on your current dose and how your body responds
Hydration/GI : nausea, vomiting, diarrhoea, reduced intakegiven explicit dehydration precautions in EU/US documents
Additionally, individual results may vary and it is always recommended to consult with a healthcare provider before starting any new supplement regimen
Phase 1 data published 2021, Phase 2 data published 2023 (NEJM), the Phase 3 program TRIUMPH is ongoing: TRIUMPH-1 , Phase 3 obesity without T2D (n=2,100), results Q4 2025 TRIUMPH-2 , Phase 3 obesity + T2D (n=1,800), results 2026 TRIUMPH-3 , Phase 3 obesity + CV disease (n=1,900), results 2026 TRIUMPH-4 , Phase 3 obesity + knee osteoarthritis, results 2026 TRIUMPH-OUTCOMES , Phase 3 cardiovascular outcome trial (n=15,000+), results 2027 to 2028 FDA approval is expected at the earliest 2026 to 2027 in the obesity indication, similarly for T2DM
US$ 20.24
US$ 28.38
US$ 26.46
US$ 20.80
US$ 29.74
US$ 24.72
US$ 26.06
US$ 23.44
US$ 27.10
US$ 288450.00
Sold : Login>>